Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the latest three months for which you have data?
Name of medicine
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Anastrozole (anastrozole or Arimidex)
1.4 Exemestane (exemestane or Aromasin)
1.5 Fulvestrant (fulvestrant or Faslodex)
1.6 Letrozole (letrozole or Femara)
1.7 Palbociclib (Ibrance)
1.8 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received abemaciclib (Verzenios) as adjuvant treatment.
Q3. How many patients received abemaciclib in combination with an aromatase inhibitor (anastrozole or exemestane or letrozole) for early breast cancer and locally advanced or metastatic breast cancer in the latest three months for which you have data?
3.1 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
3.2 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
Q4. How many patients received Olaparib (Lynparza) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received Olaparib (Lynparza) as adjuvant treatment.
Q5. How many patients were treated with the following medicines in combination in the latest three months for which you have data?
Name of combination
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
4.2 Abemaciclib (Verzenios) + Anastrozole (anastrozole or Arimidex)
4.3 Abemaciclib (Verzenios) + Exemestane (exemestane or Aromasin)
4.4 Abemaciclib (Verzenios) + Letrozole (letrozole or Femara)
4.7 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
4.8 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
4.9 Palbociclib (Ibrance) + Anastrozole (anastrozole or Arimidex)
4.10 Palbociclib (Ibrance) + Exemestane (exemestane or Aromasin)
4.11 Palbociclib (Ibrance) + Letrozole (letrozole or Femara)
4.12 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
4.13 Ribociclib (Kisqali) + Anastrozole (anastrozole or Arimidex)
4.14 Ribociclib (Kisqali) + Exemestane (exemestane or Aromasin)
4.15 Ribociclib (Kisqali) + Letrozole (letrozole or Femara)
Q5. How many patients were treated with Olaparib (Lynparza) as monotherapy for locally advanced or metastatic breast cancer in the latest three months for which you have data?
Q6. Which of these protocols does your Trust follow when issuing prescriptions for aromatase inhibitors (anastrozole or exemestane or letrozole) prescribed in combination with CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib)?
6.1 Aromatase inhibitors and CDK4/6 inhibitors are issued together To Take Out at the hospital
6.2 Aromatase inhibitors and CDK4/6 inhibitors are issued separately. The CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib) are issued To Take Out at the hospital. The aromatase inhibitors (anastrozole or exemestane or letrozole) are issued as an FP10 to the patient or a request is sent to the GP to issue in the community
6.3 Both protocols above
